Le gène suppresseur de tumeurs TP53: Vingt ans (et dix mille mutations) après

Bulletin du Cancer

Volumn 87, Issue 1, 2000, Pages 11-18

  Hainaut, Pierre ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 3;

CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; DNA DAMAGE; GENE MUTATION; HUMAN; ONCOGENE; PRECANCER; REVIEW; TUMOR SUPPRESSOR GENE; APOPTOSIS; DNA REPAIR; DRUG EFFECT; EDITORIAL; GENE EXPRESSION REGULATION; GENETICS; NEOPLASM; PHYSIOLOGY; TRANSACTIVATION;

APOPTOSIS; CELL CYCLE; DNA DAMAGE; DNA REPAIR; GENE EXPRESSION REGULATION; GENES, P53; HUMANS; NEOPLASMS; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033975238     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Harris CC. p53 tumor suppressor gene: from the basic research laboratory to the clinic: an abridged historical perspective. Carcinogenesis 1996 ; 17 : 1187-98.
2. Hainaut P, Hollstein M. p53 and human cancer : the first ten thousand mutations. Adv Cancer Res 2000 ; 77 : 82-137.
3. Prives C. Signaling to p53 : breaking the MDM2-p53 circuit. Cell 1998 ; 95 : 5-8.
4. Oren M, Rotter V. Introduction : p53, the first twenty years. Cell Mol Life Sei 1999; 55: 9-11.
5. Gottlieb TM, Oren M. p53 and apoptosis. Semin Cancer Biol 1998 ; 8:359-68.
6. Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P. IARC p53 mutation database : a relational database to compile and analyse p53 mutations in human tumors and cell lines. Human Mutation 1999 : 1-8.
7. Beroud C, Soussi T. p53 gene mutation : software and database. Nucleic Acids Res 1998 ; 26 : 200-4.
8. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function : differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999 ; 18 : 477-85.
9. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, et al. Gain of function mutations in p53. Nature Genet 1993 ; 4 : 42-6.
10. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997 ; 386 : 761-3.
11. Delmolino L, Band H, Band V. Expression and stability of p53 protein in normal human mammary epithelial cells. Carcinogenesis 1993 ; 14 : 827-32.
12. Kastan MB. Signalling to p53 : where does it all start ? Bioessays 1996 ; 18 : 617-9.
13. North S, El-Ghissassi F, Verhaegh GW, Hainaut P. The cytoprotector amifostine (WR2721) activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene 1999 (sous presse).
14. Kirch HC, Flaswinkel S, Rumpf H, Brockmann D, Esche H. Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max. Oncogene 1999 ; 18 : 2728-38.
15. Schreiber M, Kolbus A, Piu F, SzabowskiA, Mohle-Steinlein U, TianJ, et al. Control of cell cycle progression by c-Jun is p53 dependent. : Genes Dev 1999 ; 13 : 607-19.
16. HuppTR, Lane DP. Allosteric activation of latent p53 tetramers. Curr Biol 1994 ; 4 : 865-75.
17. Mummenbrauer T, Janus F, Muller B, Wiesmuller L, Deppert W, Grosse F. p53 protein exhibits 3'-to-5' exonuclease activity. Cell 1996 ; 85 : 1089-99.
18. Marechal V. Mdm2, p53 and the cell cycle : when well enough is best left alone. Pathol Biol (Paris) 1997 ; 45 : 824-32.
19. Piette J, Neel H, Maréchal V. Mdm2 : keeping p53 under control. Oncogene 1997 ; 15 : 1001-10.
20. Fuchs SY, Adler V, Buschmann T, Yin Z, Wu X, Jones SN, Ronai Z. JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev 1998 ; 12 : 2658-63.
21. Van Etten RA. Cycling, stressed-out and nervous cellular functions of c-Abl. Trends Cell Biol 1999 ; 9 : 179-86.
22. Shieh SY, Taya Y, Prives C. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J 1999 ; 18 : 1815-23.
23. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acerylation of the p53 C-terminal domain. Cell 1997 ; 90 : 595-606.
24. Waterman MJ, Stavridi ES, Waterman JL, Halazonetis TD. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nature Genet 1998 ; 19 : 175-8.
25. Meplan C, Richard MJ, Hainaut P. Redox signalling and transition metals in the control of the p53 pathway. Biochem Pharmacol 1999 (in press).
26. An WG, Kanekal M, Simon MC, Maltepc E, Blagosklonny MV, Neckers LM. Stabilization of wild-type p53 by hypoxia-inducible factor 1 alpha. Nature 1998 ; 392 : 405-8.
27. Honda R, Yasuda H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 1999 ; 18 : 22-7.
28. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998 ; 95 : 8292-7.
29. Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998 ; 92 : 713-23.
30. Russo T, Zambrano N, Esposito F, Ammendola R, Cimino F, Fiscella M, et al. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J Biol Chem 1995 ; 270 : 29386-91.
31. Kaelin WGJ. Another p53 Doppelganger ? Science 1998 ; 281 : 57-8.
32. Agami R, Blandino G, Oren M, Shaul Y. Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature 1999 ; 399 : 809-13.
33. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 1999 ; 399 : 814-7.
34. Donehower LA. The p53-deficient mouse: a model for basic and applied cancer studies. Semin Cancer Biol 1996 ; 7 : 269-78.
35. DengC, Zhang P, Harper JW, ElledgeSJ, Leder P. Mice lacking p21CIPl/WAFl undergo normal development, but are defective in G1 checkpoint control. Cell 1995 ; 82 : 675-84.
36. Hollander MC, Sheikh MS, Bulavin DV, Lundgren K, Augeri-Henmueller L, Shehee R, et al. Genomic instability in Gadd45a-deficient mice. Nature Genet 1999 ; 23 : 176-84.
37. Rogan EM, Bryan TM, Hukku B, Maclean K, Chang AC, Moy EL, et al. Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol 1995 ; 15 : 4745-53.
38. Linke SP, Clarkin KC, Wahl GM. p53 mediates permanent arrest over multiple cell cycles in response to gamma-irradiation. Cancer Res 1997 ; 57 : 1171-9.
39. Wilson JW, Pritchard DM, Hickman JA, Potten CS. Radiation-induced p53 and p21WAF-l/CIPl expression in the murine intestinal epithelium : apoptosis and cell cycle arrest. AmJ Pathol 1998 ; 153 : 899-909.
40. Lane DP. Cancer. p53, guardian of the genome. Nature 1992 ; 358 : 15-6.
41. Ponten F, Williams C, Ling G, Ahmadian A, Nister M, Lundeberg J, et al. Genomic analysis of single cells from human basal cell cancer using laser-assisted capture microscopy. Mutat Res 1997 ; 382 : 45-55.
42. Jonason AS, Kunala S, Price GJ, Restifo RJ, Spinelli HM, Persing JA, et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA 1996 ; 93 : 14025-9.
43. Sidransky D, Hollstein M. Clinical implications of the p53 gene. Anna Rev Med 1996 ; 47 : 285-301.
44. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996 ; 274 : 373-6.
45. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995 ; 83 : 237-45.
46. Selivanova G, lotsova V, Okan I, Pritsche M, Strom M, Groner B, et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nature Med 1997 ; 3 : 632-8.
47. Bottger A, Bottger V, Sparks A, Liu WL, Howard SF, Lane DP. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Can Biol 1997 ; 7 : 860-9.
48. Kramer DL, Vujcic S, Diegelman P, AlderferJ, Miller JT, Black JD, tt at. Polyamine analogue induction of the p53-p21WAFl/CIPl-Rb pathway and Gl arrest in human melanoma cells. Cancer Res 1999 ; 59 : 1278-86.
49. Ray RM, Zimmerman BJ, McCormack SA, Patel TB, Johnson LR. Polyamine depletion arrests cell cycle and induces inhibitors p21(Wafl/Cipl), p27(Kipl), and P53 in IEC-6 cells. Am J Physiol 1999 ; 276 : C684-C91.
50. Anker P, Lefort F, Vasioukhin V, Lyautey J, Lederrey C, Chen XQ, tt al. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 1997 ; 112 : 1114-20.
51. Kirk GD, Camus-Randon AM, Mendy M, Goedert JJ, Merle P, Trepo C, et al. 249ser p53 mutations in plasma from hepatocellular carcinoma patients from The Gambia, West Africa. J Natl Cancer Inst 1999 (in press).